SAN DIEGO (AP) _ Arcturus Therapeutics (ARCT) on Thursday reported a loss of $7.4 million in its third quarter.
On a per-share basis, the San Diego-based company said it had a loss of 56 cents.
The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.
The pharmaceutical company posted revenue of $3.3 million in the period, which also did not meet Street forecasts. Three analysts surveyed by Zacks expected $7.6 million.
Arcturus Therapeutics shares have more than doubled since the beginning of the year. In the final minutes of trading on Thursday, shares hit $10.30, a climb of 49% in the last 12 months.